Dynacure IPO Presentation Deck | Slidebook.io

Dynacure IPO Presentation Deck

July 2021, 33 slides

| Dynacure

| Dynacure

offering summary | Dynacure

our focus changing the lives of patients with and myopathies | Dynacure

clinical stage developing novel therapies to transform the lives of patients with serious life threatening rare diseases | Dynacure

leadership combines rare disease with broad industry experience | Dynacure

from concept to clinic in years | Dynacure

advancing multiple programs focused on neuromuscular neurodegenerative disorders | Dynacure

patient pool us japan with a significant market potential | Dynacure

our population is of patients in the | Dynacure

is a group of diseases of muscle structure and function where the muscle fibers are compromised sleeping but not | Dynacure

genes mutated in the classical forms of function common membrane remodeling pathway | Dynacure

targeting showed dose dependent muscle uptake of and reduction of protein in mouse model | Dynacure

protein reduction resulted in prolongation of and improved muscle function | Dynacure

dose dependent improvement in muscle structure following protein reduction | Dynacure

proof of concept in mouse model with data showing disease reversion | Dynacure

unite phase trial to evaluate safety tolerability and signs of efficacy in patients | Dynacure

| Dynacure

recently received clearance to proceed with unite in the | Dynacure

path to submission in a broad patient population | Dynacure

year natural history study ongoing in expanding in us | Dynacure

in discovery for | Dynacure

hereditary spastic paraplegia is a group of severe rare neurodegenerative disorders with no current treatment | Dynacure

loss of gene promotes accumulation of and neuronal death a | Dynacure

decreasing synthesis as a potential therapeutic option for pathology initial target validation data | Dynacure

anticipated milestones and conclusion | Dynacure

substantial progress already made multiple near term milestones expected in | Dynacure

funding history rounds to date | Dynacure

clinical stage developing novel therapies to transform be ree will core | Dynacure

appendix a | Dynacure

is born out of a complementary collaboration | Dynacure

features and treatment options for and | Dynacure

targeting to reduce expression and treat most common forms of cum ghost aint | Dynacure

See More

Dynacure

IPO Presentation Decks

Explore Topics

Rare disease

Clinical trial

Search Thousands of Presentations by World Leading Companies

Trending:

Addressable Market

Management Team

Investment Highlights